Taken together, our findings suggest that assessment of the methylation status of both RASSF1‐1α and RASSF1‐2γ promoters can be a refined tool for breast cancer patient stratification and concurs to provide a more sensitive prognostic signature than the use of RASSF1‐1α methylation alone. This evidence concerns the gene RASSF1 and breast carcinoma.